^
Association details:
| Biomarker: | MYC rearrangement + BCL2 rearrangement |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | Zynlonta (loncastuximab tesirine-lpyl) (DNA replication inhibitor, CD19-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
177 | LOTIS 2 follow-up analysis: Updated results from a Phase 2 study of loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma
Published date:
06/09/2021
Excerpt:
145 pts with R/R DLBCL received ≥1 dose of Lonca....ORR for pts with double-/triple-hit DLBCL was 33.3%... After longer follow-up of pts in LOTIS 2, durable responses to Lonca continue to be observed in heavily pre-treated pts with R/R DLBCL.
Trial ID:
